semaglutide tirzepatide weight loss injections Maintenance therapy on or Semaglutide vs Tirzepatide: Which Is

SURMOUNT-1 clinical trial showed mean % weight losses at week 72 were 15% (95% CI 15.9 to 14.2), 19.5% (95% CI 20.4 to 18.5), 20.9% (95% CI 21.8 to 19.9) and 3.1% (95% CI 4.3 to 1.9) with 5 mg/week, 10 mg/week, 15 mg/week Tirzepatide and placebo, respectively ( p 5% weight at six months

Patients who are reassuringly labeled no apparent retinopathy or mild non-proliferative retinopathy on seven-field photography frequently already harbor substantial, widespread, and potentially reversible functional damage when examined with wider-field or multifocal techniques

A failure here compromises the entire endeavor

As suggested by Shah et al

Cancer Res 75(21):45044516 Lugano R et al (2018) CD93 promotes beta1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis

This sets up a deeper discussion about the physiological basis of appetite control